Patent ID: 8685404
Filing Date: 2014-04-01
Classification: A61B,A61K,A61P,C07K

Abstract:
1. A method for treating cognitive or neuropsychiatric impairment induced by substance addiction, comprising selecting a subject with a substance addiction; and administering to the subject a therapeutically effective amount of a Major Histocompatibility Complex (MHC) molecule comprising covalently linked first, second and third domains, wherein: the first domain is an MHC class II β1 domain and the second domain is an MHC Class II α1 domain, wherein the amino terminus of the α1 domain is covalently linked to the carboxy terminus of the β1 domain, wherein the MHC molecule does not comprise an MHC class II α2 domain or an MHC Class II β2 domain, and wherein the third domain is covalently linked to the first domain, wherein the third domain comprises an antigenic determinant, wherein the antigenic determinant is MOG 35-55; thereby treating the cognitive or neuropsychiatric impairment in the subject, wherein the subject does not have multiple sclerosis or a stroke.